Evidence map›Paper›PMID 33808901›Full record

ReviewPharmaceutics2021

Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients.

Theerawut Klangjareonchai, Natsuki Eguchi, Ekamol Tantisattamo, Antoney J Ferrey, Uttam Reddy, Donald C Dafoe, Hirohito Ichii

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Applications and prospects of biomaterials in diabetes management.Frontiers in bioengineering and biotechnology · 2025
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Theerawut KlangjareonchaiDivision of Transplantation, Department of Surgery, University of California, Irvine, Orange, CA 92868, USA.
Natsuki EguchiDivision of Transplantation, Department of Surgery, University of California, Irvine, Orange, CA 92868, USA.
Ekamol TantisattamoDivision of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California, Irvine, Orange, CA 92868, USA.ORCID 0000-0003-0883-6892
Antoney J FerreyDivision of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California, Irvine, Orange, CA 92868, USA.
Uttam ReddyDivision of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California, Irvine, Orange, CA 92868, USA.
Donald C DafoeDivision of Transplantation, Department of Surgery, University of California, Irvine, Orange, CA 92868, USA.
Hirohito IchiiDivision of Transplantation, Department of Surgery, University of California, Irvine, Orange, CA 92868, USA.ORCID 0000-0002-3635-5773
University of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperglycemia after kidney transplantation is common in both diabetic and non-diabetic patients. Both pretransplant and post-transplant diabetes mellitus are associated with increased kidney allograft failure and mortality. Glucose management may be challenging for kidney transplant recipients. The pathophysiology and pattern of hyperglycemia in patients following kidney transplantation is different from those with type 2 diabetes mellitus. In patients with pre-existing and post-transplant diabetes mellitus, there is limited data on the management of hyperglycemia after kidney transplantation. The following article discusses the nomenclature and diagnosis of pre- and post-transplant diabetes mellitus, the impact of transplant-related hyperglycemia on patient and kidney allograft outcomes, risk factors and potential pathogenic mechanisms of hyperglycemia after kidney transplantation, glucose management before and after transplantation, and modalities for prevention of post-transplant diabetes mellitus.

Indexed as

cyclosporinediabetes mellitusdipeptidyl peptidase-4 (DDP-4) inhibitorskidney transplantnew onset diabetes after transplantation (NODAT)post-transplant diabetes mellitus (PTDM)tacrolimus

Identifiers

PMID33808901
PMCPMC8003701
OpenAlexW3137003452

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.